# CAi Copilot: Reducing Operational Workload in Molecular Design through Intent-Driven Agentic Workflows

arXiv: https://arxiv.org/abs/2608.06961 · HTML: https://mlsanity.com/paper/2608.06961/

## Key facts

- Cited by 1 papers in the map (data through 14 Oct 2026).
- Placed in Medical and scientific domain agents, one of 16 directions in LLM agents and tool use.
- Builds on 17 of its 33 references that are in the map.
- First posted on arXiv 7 Aug 2026.

## Placed in

- LLM agents and tool use / [Medical and scientific domain agents](https://mlsanity.com/agents/medical-and-scientific-domain-agents/)

## Builds on (most cited first, 17 of 17)

- [ChemCrow: Augmenting large-language models with chemistry tools](https://mlsanity.com/paper/2304.05376/) (2023)
- [Accelerating scientific discovery with Co-Scientist](https://mlsanity.com/paper/2502.18864/) (2025)
- [Pocket2Mol: Efficient Molecular Sampling Based on 3D Protein Pockets](https://mlsanity.com/paper/2205.07249/) (2022)
- [Translation between Molecules and Natural Language](https://mlsanity.com/paper/2204.11817/) (2022)
- [Mol-Instructions: A Large-Scale Biomolecular Instruction Dataset for Large Language Models](https://mlsanity.com/paper/2306.08018/) (2023)
- [LlaSMol: Advancing Large Language Models for Chemistry with a Large-Scale, Comprehensive, High-Quality Instruction Tuning Dataset](https://mlsanity.com/paper/2402.09391/) (2024)
- [ChemLLM: A Chemical Large Language Model](https://mlsanity.com/paper/2402.06852/) (2024)
- [DecompDiff: Diffusion Models with Decomposed Priors for Structure-Based Drug Design](https://mlsanity.com/paper/2403.07902/) (2024)
- [An AI system to help scientists write expert-level empirical software](https://mlsanity.com/paper/2509.06503/) (2025)
- [TxAgent: An AI Agent for Therapeutic Reasoning Across a Universe of Tools](https://mlsanity.com/paper/2503.10970/) (2025)
- [RGFN: Synthesizable Molecular Generation Using GFlowNets](https://mlsanity.com/paper/2406.08506/) (2024)
- [SynFlowNet: Design of Diverse and Novel Molecules with Synthesis Constraints](https://mlsanity.com/paper/2405.01155/) (2024)
- [LIDDIA: Language-based Intelligent Drug Discovery Agent](https://mlsanity.com/paper/2502.13959/) (2025)
- [Large Language Model Agent for Modular Task Execution in Drug Discovery](https://mlsanity.com/paper/2507.02925/) (2025)
- [Generation of 3D Molecules in Pockets via Language Model](https://mlsanity.com/paper/2305.10133/) (2023)
- [MolClaw: An Autonomous Agent with Hierarchical Skills for Drug Molecule Evaluation, Screening, and Optimization](https://mlsanity.com/paper/2604.21937/) (2026)
- [SMDD-Bench: Can LLMs Solve Real-World Small Molecule Drug Design Tasks?](https://mlsanity.com/paper/2605.21740/) (2026)

## Built on by (most cited first, 1 of 1)

- [Science Done on a Machine by a Machine: AI Agents in Computational Chemistry](https://mlsanity.com/paper/2608.18508/) (2026)

## Abstract (arXiv)

Early-stage molecular design is an iterative process, not just a task of generating molecules. Researchers turn broad goals into design strategies, refine candidates, assess many properties, and gather evidence before synthesis and tests. AI methods can generate molecules, optimize several goals, predict properties, dock compounds, and account for synthesis. Yet these functions are spread across specialized tools. Experts must still coordinate each step, judge interim results, and integrate evidence. The central challenge is thus to turn research intent into adaptive, traceable runs grounded in scientific tools. We cast this challenge as intent-to-evidence molecular design workflow execution and present CAi Copilot, an expert-oriented agent with three linked layers. The Research Interface Layer turns intent into an executable plan. The Agent Reasoning Layer uses interim results to guide each run. The Execution Substrate supplies molecular tools, metrics, reusable utilities, and backend services. Across 45 tasks, CAi achieves the strongest overall performance, with an outcome score of 84.59, exceeding the next-best result by 18.07 points. Additional benchmarks test how CAi coordinates generation, screening, and multi-criteria evaluation, while exposing limits in long-horizon execution. These results show that CAi turns broad molecular-design intent into transparent, traceable workflows that connect interim decisions to candidate-level evidence.